Literature DB >> 32895249

Acquired haemophilia a secondary to multiple myeloma: management of a patient with a mechanical mitral valve.

Lisa B Pinchover1, Rami Alsharif2, Talia Bernal3.   

Abstract

A 77-year-old man with a mechanical mitral valve on warfarin presented with an acute drop in haemoglobin and large spontaneous haematoma. He was found to have a new coagulopathy with initial labs notable for a prolonged activated partial thromboplastin time (APTT). Further workup revealed factor VIII levels less than 1%, abnormal mixing studies and elevated Bethesda titres, which was consistent with an acquired factor VIII inhibitor. Given his bone marrow biopsy result, which was positive for plasma cell myeloma, this coagulopathy was thought to be an acquired haemophilia A secondary to multiple myeloma. Anticoagulation was a challenge in this patient given his mechanical mitral valve and acquired haemophilia A. Although the patient was at risk of thrombosis due to a mechanical mitral valve, he had a bleeding diathesis and anaemia not responsive to transfusion. The decision was made to hold anticoagulation and the patient was started on myeloma treatment which included CyBorD, rituximab and daratumumab. After initiation of treatment APTT and factor VIII normalised. He eventually restarted anticoagulation under direction of his primary care doctor. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  haematology (drugs and medicines); haematology (incl blood transfusion); medical management; valvar diseases

Mesh:

Substances:

Year:  2020        PMID: 32895249      PMCID: PMC7476471          DOI: 10.1136/bcr-2019-230798

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

Review 1.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

2.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas
Journal:  Circulation       Date:  2014-03-03       Impact factor: 29.690

Review 3.  Acquired hemophilia A: a concise review.

Authors:  Massimo Franchini; Giorgio Gandini; Tiziana Di Paolantonio; Guglielmo Mariani
Journal:  Am J Hematol       Date:  2005-09       Impact factor: 10.047

Review 4.  Acquired factor VIII inhibitors.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood       Date:  2008-05-07       Impact factor: 22.113

Review 5.  Acquired haemophilia in cancer: A systematic and critical literature review.

Authors:  M Napolitano; S Siragusa; S Mancuso; C M Kessler
Journal:  Haemophilia       Date:  2017-09-27       Impact factor: 4.287

6.  Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Authors:  Kenneth C Anderson; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Benjamin Djulbegovic; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Shaji K Kumar; Michaela Liedtke; Matthew Lunning; Noopur Raje; Seema Singhal; Clayton Smith; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2015-11       Impact factor: 11.908

7.  International recommendations on the diagnosis and treatment of acquired hemophilia A.

Authors:  Andreas Tiede; Peter Collins; Paul Knoebl; Jerome Teitel; Craig Kessler; Midori Shima; Giovanni Di Minno; Roseline d'Oiron; Peter Salaj; Victor Jiménez-Yuste; Angela Huth-Kühne; Paul Giangrande
Journal:  Haematologica       Date:  2020-05-07       Impact factor: 9.941

Review 8.  Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.

Authors:  Larysa Sanchez; Yucai Wang; David S Siegel; Michael L Wang
Journal:  J Hematol Oncol       Date:  2016-06-30       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.